Biofrontera quadruples shareholder base and increases trading volume
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Leverkusen, Germany, - Biofrontera (DSE: B8F) announces that itsshareholder base has grown four-fold to about 1200 shareholders sincethe beginning of the year. At the same time the liquidity of thestock has greatly increased. Compared to the last months of thepreceding year the recent daily trading was 10 to 20 times higher.Trading volumes in the five-digit range, which were exceptional lastyear, are now common. Even the trading of more than 100,000 sharesper day has occasionally occurred without major movements of thestock price.With the three capital increases that Biofrontera has, in spite ofthe difficult market conditions, been able to close this year, thecompany's share number increased to 7.6 mln. In parallel, thefree-float grew to over 60%, such that the majority of the shares isnow held by small funds and private investors.The market launch of the medical cosmetic Belixos®, occurring at thelargest European dermatology congress at the beginning of October,has been very successful. In the meantime the direct marketingthrough Biofrontera's dermatology sales force was initiated. Belixos®is a cream with purely herbal ingredients which was specificallydeveloped for the daily care of irritated and inflamed skin. Due tothe initial concentration of the marketing efforts on selectedcompetence centers the users of the cream will obtain expert advice.This has led to very positive resonance on the daily use of Belixos®cream that has particularly been expressed by patients with skindiseases like atopic dermatitis or psoriasis.With the ongoing data analysis of the last pivotal trial with BF-200ALA for the treatment of actinic keratosis the filing for themarketing authorization with the EMEA in Q3 2010 comes close.Short-term, Biofrontera anticipates forming license and distributionagreements with strong international partners focusing on thedermatology market."The significant expansion of the shareholder base and the increasedliquidity of the stock reflect the positive development ofBiofrontera's business. They serve as important benchmarks, whichfind strong attention when addressing investment groups," commentedWerner Pehlemann, CFO of Biofrontera AG, the development.About Biofrontera AGBiofrontera AG is specialized in the development of pharmaceuticalproducts in the area of dermatology. The company is characterized bya broad, relatively close to the market product portfolio.Biofrontera is listed in the regulated market of the Düsseldorf stockexchange under the symbol B8F and the ISIN DE0006046113.This press release contains forward-looking statements based on thecurrently held beliefs and assumptions of the management ofBiofrontera AG, which are expressed in good faith and, in theiropinion, reasonable. Forward-looking statements involve known andunknown risks, uncertainties and other factors, which may cause theassumptions expressed or implied in this press release to be faulty.Given these risks, uncertainties and other factors, recipients ofthis document are cautioned not to place undue reliance on theforward-looking statements. Biofrontera AG disclaims any obligationto update these forward-looking statements to reflect future eventsor developments.For further information please contact:Anke zur MühlenCorporate Communication+ 49 (0) 214 87632 22+ 49 (0) 214 87632 90a.zurmuehlen(at)biofrontera.comBiofrontera AGHemmelrather Weg 201D- 51377 Leverkusen, Germany --- End of Message ---Biofrontera AGHemmelrather Weg 201 Leverkusen GermanyWKN: 604611; ISIN: DE0006046113; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;
Datum: 28.10.2009 - 09:54 Uhr
Sprache: Deutsch
News-ID 7527
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 301 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera quadruples shareholder base and increases trading volume"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
